Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in treatment-naive sub-foveal CNV secondary to AMD
NCT00712491Phase 2Terminated
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2008
- Primary completion
- Nov 2009
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in age-related macular degeneration (AMD), choroidal neovascularization (CNV), sponsored by Santen Pharmaceutical. Started Sep 2008; status: terminated.
02
Drugs
sirolimus
03
Conditions
age-related macular degeneration (AMD)choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT00712491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00712491.